Pete Salzmann is the founder of Immunovant. Immunovant has raised $450M in total funding. Latest round: Post-IPO. Backed by Roivant. Based in New York, NY.
Pete Salzmann is the Chief Executive Officer of Immunovant, a clinical-stage immunology company focused on developing therapies for autoimmune diseases. Immunovant recently announced a private placement of $450 million to advance its development pipeline and for general corporate purposes.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide